Use of bisphosphonates and risk of postmenopausal breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages 3577-3581

  Rennert, Gad ^a   Pinchev, Mila ^a   Rennert, Hedy S ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; BONE DENSITY CONSERVATION AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BREAST CANCER; BREAST FEEDING; CALCIUM INTAKE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC GROUP; FAMILY HISTORY; FEMALE; FOOD INTAKE; FRUIT; HEALTH SERVICE; HORMONE SUBSTITUTION; HUMAN; INTRADUCTAL CARCINOMA; ISRAEL; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PHARMACY; PHYSICAL ACTIVITY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; SPORT; TREATMENT DURATION; VEGETABLE; BREAST TUMOR; ETHNOLOGY; MIDDLE AGED; NEOPLASM; RISK; TIME;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; ISRAEL; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RISK; TIME FACTORS;

EID: 77955870208     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.1113     Document Type: Article

References (29)

1. Aapro M, Abrahamsson PA, Body JJ, et al: Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 19:420-432, 2008
2. Valverde P: Pharmacotherapies to manage bone loss-associated diseases: A quest for the perfect benefit-to-risk ratio. Curr Med Chem 15:284-304, 2008
3. Lipton A: Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34:S25-S30, 2008 (suppl 1)
4. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
5. Park IH, Ro J, Nam BH, et al: Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases. BMC Cancer 9:154, 2009
6. Russell RG, Watts NB, Ebetino FH, et al: Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759, 2008
7. Green JR: Antitumor effects of bisphosphonates. Cancer 97:840-847, 2003 (suppl)
8. Wiemer AJ, Hohl RJ, Wiemer DF: The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med Chem 9:526-542, 2009
9. Rachner TD, Singh SK, Schoppet M, et al: Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287:109-116, 2010
10. Yizhaki D, Rennert HS, Rosen G, et al: Validity and reproducibility of a semi-quantitative food frequency questionnaire adapted to an Israeli population. The Open Nutrition Journal 2:9-14, 2008
11. Rennert G: Breast cancer, in Freedman LS, Edwards BK, Ries LAG, et al (eds): Cancer Incidence in Four Member Countries of the Middle Eastern Cancer Consortium (MECC) Compared with US SEER. Bethesda, MD, National Cancer Institute, NIH publication 06-5873, 2006
12. Powles T, Paterson S, Kanis JA, et al: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224, 2002 (Pubitemid 34831518)
13. Diel IJ, Solomayer EF, Costa SD, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998 (Pubitemid 28363797)
14. Clézardin P: The antitumor potential of bisphosphonates. Semin Oncol 29:33-42, 2002 (suppl 21)
15. Stresing V, Daubiné F, Benzaid I, et al: Bisphosphonates in cancer therapy. Cancer Lett 257:16-35, 2007 (Pubitemid 47464698)
16. Green J, Gschaidmeier H, Yoneda T, et al: Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol 11:14, 2000 (suppl 4)
17. Peyruchaud O, Winding B, Pecheur I, et al: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16:2027-2034, 2001 (Pubitemid 32995393)
18. Nobuyuki H, Hiraga T, Williams PJ, et al: The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J Bone Miner Res 16:S191, 2001 (suppl 1)
19. Watson J, Wise L, Green J: Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 63:843-849, 2007
20. Bundred NJ, Campbell ID, Davidson N, et al: Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001-1010, 2008 (Pubitemid 351304583)
21. Loke YK, Jeevanantham V, Singh S: Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Saf 32:219-228, 2009
22. Etminan M, Lévesque L, Fitzgerald JM, et al: Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: A case-control study. Aliment Pharmacol Ther 29:1188-1192, 2009
23. Solomon DH, Rekedal L, Cadarette SM: Osteoporosis treatments and adverse events. Curr Opin Rheumatol 21:363-368, 2009
24. Chen Z, Arendell L, Aickin M, et al: Women's Health Initiative Program, National Heart, Lung and Blood Institute, US Department of Health and Human Services: Hip bone density predicts breast cancer risk independently of Gail score: Results from the Women's Health Initiative. Cancer 113:907-915, 2008
25. Cauley JA, Lucas FL, Kuller LH, et al: Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures: Study of Osteoporotic Fractures Research Group. JAMA 276:1404-1408, 1996 (Pubitemid 26365846)
26. Buist DS, LaCroix AZ, Barlow WE, et al: Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol 54:417-422, 2001 (Pubitemid 32303466)
27. Licata AA: Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39:668-677, 2005
28. Stahlberg C, Pedersen AT, Andersen ZJ, et al: Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 91:644-650, 2004 (Pubitemid 39141618)
29. Borgquist S, Anagnostaki L, Jirström K, et al: Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 120:2202-2207, 2007 (Pubitemid 46555859)